Daily Respiratory Research Analysis
A phase 4 randomized trial showed dupilumab reduced type 2 airway inflammation and mucus plugging while improving airflow in uncontrolled moderate-to-severe asthma. A large randomized trial in COPD patients undergoing bronchoscopy found high-flow nasal oxygen significantly reduced hypoxemia without affecting comfort. A global analysis revealed a consistent, asynchronous resurgence of common respiratory viruses post–COVID-19, informing surveillance and vaccination timing.
Summary
A phase 4 randomized trial showed dupilumab reduced type 2 airway inflammation and mucus plugging while improving airflow in uncontrolled moderate-to-severe asthma. A large randomized trial in COPD patients undergoing bronchoscopy found high-flow nasal oxygen significantly reduced hypoxemia without affecting comfort. A global analysis revealed a consistent, asynchronous resurgence of common respiratory viruses post–COVID-19, informing surveillance and vaccination timing.
Research Themes
- Biologic therapy and imaging biomarkers in asthma
- Peri-procedural oxygenation strategies in bronchoscopy for COPD
- Post-pandemic dynamics of respiratory viruses and surveillance policy
Selected Articles
1. Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial.
Dupilumab significantly increased the proportion of patients achieving FeNO <25 ppb (57% vs 11%; OR 9.8) and reduced CT-derived mucus plugging compared with placebo. Functional respiratory imaging showed increases in specific airway volume and flow, consistent with improvements in lung function and asthma control over 24 weeks.
Impact: This RCT links a biologic’s anti–type 2 effects to quantifiable airway remodeling and mucus plugging via advanced imaging, offering mechanistic and clinically relevant endpoints beyond standard spirometry.
Clinical Implications: Dupilumab may benefit T2-high asthma by reducing mucus plugging and improving regional airflow; functional respiratory imaging could serve as a biomarker to phenotype patients and monitor response.
Key Findings
- At week 24, FeNO <25 ppb was achieved in 57% with dupilumab vs 11% with placebo (OR 9.8, p<0.001).
- CT-based mucus plugging score decreased more with dupilumab than placebo (least squares mean difference −2.62; 95% CI −3.92 to −1.31).
- Specific regional airway volume and flow increased with dupilumab, aligning with improved lung function and asthma control.
Methodological Strengths
- Randomised, double-blind, placebo-controlled multicenter design
- Use of functional respiratory imaging with pre-specified quantitative endpoints
Limitations
- Modest sample size and 24-week duration limit long-term generalizability
- Imaging surrogates; not powered for exacerbation outcomes
Future Directions: Validate imaging biomarkers for treatment selection and response monitoring; evaluate long-term exacerbation and mucus-related outcomes; test generalizability across T2 phenotypes and comorbid mucus hypersecretion.
BACKGROUND: Asthma is a respiratory disease characterised by chronic airway inflammation and mucus hypersecretion. VESTIGE used functional respiratory imaging to assess changes in airway structure and function, including mucus plugging, in response to dupilumab. METHODS: VESTIGE was a randomised, double-blind, placebo-controlled, phase 4 trial done at 72 research sites or academic centres in 14 countries. We recruited adult patients (aged 18-70 years) with physician-diagnosed, uncontrolled, moderate-to-severe type 2 asthma (blood eosinophil count ≥300 cells/μL and fractional exhaled nitric oxide [FeNO] ≥25 parts per billion [ppb]) being treated with medium-dose to high-dose inhaled corticosteroids combined with other controller medications. Patients were randomly assigned (2:1; block size of 6) via interactive voice-web response technology to receive add-on dupilumab 300 mg subcutaneously once every 2 weeks or volume-matched placebo up to week 24. Randomisation was stratified by inhaled corticosteroids dose level and region (eastern Europe vs the rest of the world). Participants and investigators, including those assessing outcomes, were masked to group assignment. The primary endpoints were the proportion of patients with a FeNO concentration below 25 ppb at week 24, and percentage change from baseline to week 24 in airway volumes (specific regional airway volumes corrected for lung volume, [s]iV
2. Characterising the asynchronous resurgence of common respiratory viruses following the COVID-19 pandemic.
Across 92 global sites, respiratory viruses resurged after NPI relaxation in a consistent sequence with rhinovirus earliest and influenza B latest, replicated in a second wave. The patterns imply virus-intrinsic properties, not locale, govern relative resurgence timing, informing seasonality models, surveillance, and vaccine program planning.
Impact: Provides a global, cross-virus framework for anticipating off-season surges and optimizing timing of diagnostics, immunization, and health system preparedness in the post-pandemic era.
Clinical Implications: Surveillance and vaccination strategies can be tailored by anticipating virus-specific resurgence order and timing, particularly for RSV and influenza program planning and resource allocation.
Key Findings
- In the first post-pandemic resurgence, the consistent sequence was rhinovirus → seasonal coronavirus → parainfluenza → RSV → adenovirus → metapneumovirus → influenza A → influenza B.
- The second resurgence showed a similar order with influenza A catching up to metapneumovirus.
- Generalised linear mixed-effects modeling across 92 sites indicated asynchrony driven by virus-specific characteristics rather than geography.
Methodological Strengths
- Global, multi-source dataset integrating surveillance and systematic review with standardized modeling
- Cross-virus, site-level comparative analysis using mixed-effects models
Limitations
- Heterogeneity in testing practices and reporting across sites
- Observational design limits causal inference; lacks mechanistic virologic confirmation
Future Directions: Integrate climate, host immunity, and contact patterns into predictive models; link virologic features to resurgence timing; assess policy impacts on optimal immunization windows.
The COVID-19 pandemic and relevant non-pharmaceutical interventions (NPIs) interrupted the circulation of common respiratory viruses. These viruses demonstrated an unprecedented asynchronous resurgence as NPIs were relaxed. We compiled a global dataset from a systematic review, online surveillance reports and unpublished data from Respiratory Virus Global Epidemiology Network, encompassing 92 sites. We compared the resurgence timings of respiratory viruses within each site and synthesised differences in timings across sites, using a generalised linear mixed-effects model. We revealed a distinct sequential timing in the first post-pandemic resurgence: rhinovirus resurged the earliest, followed by seasonal coronavirus, parainfluenza virus, respiratory syncytial virus, adenovirus, metapneumovirus and influenza A virus, with influenza B virus exhibiting the latest resurgence. Similar sequential timing was observed in the second resurgence except influenza A virus caught up with metapneumovirus. The consistent asynchrony across geographical regions suggests that virus-specific characteristics, rather than location-specific factors, determining the relative timing of resurgence.
3. Preventing oxygen desaturation during bronchoscopy in COPD patients using high-flow oxygen
In 600 COPD patients undergoing bronchoscopy, high-flow nasal oxygen reduced cumulative hypoxemia time by 53% and decreased hypoxemia events versus low-flow oxygen, without affecting patient comfort. The strategy is feasible during conscious sedation and addresses a key procedural risk in COPD.
Impact: Provides high-quality, procedure-focused evidence to improve safety in a common high‑risk COPD scenario, with clear, actionable practice change (use of HFNO during bronchoscopy).
Clinical Implications: Adopt high-flow nasal oxygen during bronchoscopy in COPD patients to reduce intra-procedural hypoxemia; consider protocols that maintain comfort while mitigating desaturation risk.
Key Findings
- High-flow nasal oxygen reduced cumulative hypoxemia time by 53% compared with low-flow oxygen.
- Hypoxemia events were fewer with high-flow oxygen; patient comfort did not differ.
- Randomized trial of 600 COPD patients under conscious sedation supports feasibility and effectiveness.
Methodological Strengths
- Large randomized controlled trial with clinically relevant procedural endpoints
- Standardized oxygen delivery protocols and objective hypoxemia metrics
Limitations
- Single-centre, open-label design may limit generalizability and introduce performance bias
- Short-term peri-procedural outcomes only; no long-term follow-up
Future Directions: Multicentre blinded studies assessing subgroups (e.g., severe hypoxemia risk) and cost-effectiveness; evaluate HFNO in other bronchoscopic interventions and sedation strategies.
BACKGROUND: Patients with COPD are at increased risk for developing additional respiratory comorbidities associated with smoking, and are thus prone to undergo flexible bronchoscopy. However, COPD patients have increased periprocedural complications risk and lower oxygen saturation during bronchoscopy. METHODS: This was an investigator-initiated, single-centre, open-label randomised controlled trial designed to assess the benefits of high-flow nasal oxygen compared to conventional low-flow oxygen by nasal cannula during conscious sedation for bronchoscopy in patients with COPD. Low flow was supplied at a starting rate of 4 L·min RESULTS: We randomised 600 COPD cases with a median (interquartile range (IQR)) age of 69.0 (62.0-76.0) years to either high flow (n=295) or low flow (n=305). The cumulative hypoxaemia time was 53% lower in the high-flow group (1.8% (95% CI 1.5-2.2%) CONCLUSION: High flow is feasible, decreases cumulative hypoxaemia time and reduces hypoxaemia events during bronchoscopy in patients with COPD but does not impact patient comfort.